Australia's Imugene doubles in four days after positive cancer drug study

Imugene

09/11/2023 04:19

** Shares of Australian clinical-stage cancer drug developer
Imugene  IMU.AX  rise as much as 32.7% to A$0.108, marking their
biggest intraday pct jump since June 27 last year
    ** IMU shares have soared 114% since Nov 6, when it
announced positive early signs from its early-stage study on
cancer-killing virus
    ** IMU at its highest level since July 31 on Thursday; on
track for sixth straight day of gains, if gains hold
    ** IMU on track for its best week since early May 2012
    ** Top gainer in the ASX All Ordinaries index  .AORD 
    ** Nearly 241 mln shares change hands, vs the 30-day average
volume of 37.1 mln
    ** Stock down 44.1% YTD, based on last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))